Access
To read this story in full you will need to login or make a payment (see right).
Business
Nature 441, 281 (18 May 2006) | doi:10.1038/441281a; Published online 17 May 2006
In brief
Merck is to pay $400 million for a privately held biotechnology firm that improves drugs by fine-tuning their sugar structures. GlycoFi of Lebanon, New Hampshire, has developed technology that uses specially engineered yeasts to attach sugars to proteins with high accuracy.
To read this story in full you will need to login or make a payment (see right).